Archived Facts

FRANKFURT (Reuters) – Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than 2 billion euros ($ 2.6 billion) this year, driven by patent expiries in Europe and strong demand in the United States.

Popular Posts:

Related Posts:

Leave a Reply